Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) InjectionPRNewsWire • 11/16/21
Viatris Donates $1 Million as Founding Champion to New Orleans-based SBP's "Got Your Back" fund in Support of Housing Solutions for Veterans in Disaster-Impacted CommunitiesPRNewsWire • 11/11/21
Viatris Inc. (VTRS) CEO Michael Goettler on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/08/21
Viatris Reports Strong Third Quarter Results, Raises 2021 Financial Guidance and Announces Virtual Investor Event on January 7, 2022PRNewsWire • 11/08/21
Wall Street Analysts See a 33% Upside in Viatris (VTRS): Can the Stock Really Move This High?Zacks Investment Research • 10/22/21
Viatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest FormularyPRNewsWire • 10/20/21